<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) is a congenital <z:hpo ids='HP_0001903'>anemia</z:hpo> characterized by a low reticulocyte count, the absence or severe reduction of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>-containing cells in the bone marrow, and <z:mpath ids='MPATH_458'>normal</z:mpath> megakaryocytic and granulocytic differentiation </plain></SENT>
<SENT sid="1" pm="."><plain>Although the <z:hpo ids='HP_0001903'>anemia</z:hpo> may initially respond to <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy, many patients require lifelong red blood cell (RBC) transfusion, leading to infectious complications and <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Metoclopramide has recently been used to treat <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with metoclopramide induces the release of prolactin from the pituitary and stimulates erythropoiesis </plain></SENT>
<SENT sid="4" pm="."><plain>For these reasons, we used metoclopramide to treat a 20-year-old man with <z:chebi fb="28" ids="35299">DBA</z:chebi> refractory to low and high doses of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, and tacrolimus (FK506) </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> and hematocrit slowly increased, and he has remained asymptomatic and transfusion-independent for 8 months </plain></SENT>
<SENT sid="6" pm="."><plain>Metoclopramide therapy should be considered in patients with refractory <z:chebi fb="28" ids="35299">DBA</z:chebi> before treatment-related complications develop </plain></SENT>
</text></document>